Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912312 | 1.00 | SLC40A1 (0.39) | SLC40A1NFE2L2RAB9ASMN1; SMN2LMNA | |
| SCHEMBL27854216 | 0.82 | LMNA (0.43) | NFE2L2RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL29117972 | 0.82 | TDP2 (0.41) | SLC40A1NFE2L2RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14840705 | 0.76 | ERN1 (0.45) | NFE2L2RAB9ASMN1; SMN2LMNAERN1 | |
| SCHEMBL29118036 | 0.75 | CYP1A2 (0.46) | SLC40A1RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL95708 | 0.75 | ERN1 (0.50) | NFE2L2LMNAERN1IKBKBCES1 | |
| SCHEMBL6270187 | 0.74 | CCNE2 (0.41) | NPC1CES1 | |
| SCHEMBL29912323 | 0.74 | NFE2L2 (0.42) | NFE2L2RAB9ASMN1; SMN2ERN1NPC1 | |
| SCHEMBL17597905 | 0.74 | NFE2L2 (0.42) | NFE2L2RAB9ASMN1; SMN2ERN1NPC1 | |
| SCHEMBL31517695 | 0.73 | NPC1 (0.46) | RAB9ASMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024056016-A1 | FREE BASE CRYSTAL FORM OF POLYCYCLIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND PREPARATION METHOD THEREFOR | 江苏豪森药业集团有限公司 | 2024-03-21 | — | — | WO | claimed |
| CN-117700416-A | Salts of polycyclic compounds containing nitrogen heterocycles and process for preparing the same | 江苏豪森药业集团有限公司 | 2024-03-15 | — | — | CN | claimed |
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | claimed |
| WO-2024056016-A1 | FREE BASE CRYSTAL FORM OF POLYCYCLIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND PREPARATION METHOD THEREFOR | 江苏豪森药业集团有限公司 | 2024-03-21 | — | — | WO | disclosed |
| CN-117700416-A | Salts of polycyclic compounds containing nitrogen heterocycles and process for preparing the same | 江苏豪森药业集团有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981670-A | Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-110669052-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022194122-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-110669052-A | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | SLC40A1 446/4885NFE2L2 934/4885RAB9A 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.